Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. The company's lead product candidate, ganaxolone, is a synthetic analog of the endogenous neurosteroid allopregnanolone and is being developed in both intravenous and oral formulations for the treatment of status epilepticus, postpartum depression, and other indications. Marinus Pharmaceuticals is headquartered in Radnor, Pennsylvania.